These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Identification of predictive factors for early relapse in patients with unresectable stage III non-small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy. Nam JH; Yeo CD; Park CK; Kim SK; Kim JS; Kim YH; Kim JW; Kim SJ; Lee SH; Kang HS Thorac Cancer; 2023 Sep; 14(26):2657-2664. PubMed ID: 37519059 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors. Guberina M; Guberina N; Pöttgen C; Gauler T; Richlitzki C; Metzenmacher M; Wiesweg M; Plönes T; Forsting M; Wetter A; Herrmann K; Hautzel H; Darwiche K; Theegarten D; Aigner C; Schuler M; Stuschke M; Eberhardt WE Immunotherapy; 2022 Aug; 14(12):927-944. PubMed ID: 35822656 [TBL] [Abstract][Full Text] [Related]
7. Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab. Lebow ES; Shepherd A; Eichholz JE; Offin M; Gelblum DY; Wu AJ; Simone CB; Schoenfeld AJ; Jones DR; Rimner A; Chaft JE; Riaz N; Gomez DR; Shaverdian N JAMA Netw Open; 2023 Jan; 6(1):e2249591. PubMed ID: 36602799 [TBL] [Abstract][Full Text] [Related]
8. Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab. Bryant AK; Sankar K; Strohbehn GW; Zhao L; Daniel V; Elliott D; Ramnath N; Green MD Int J Radiat Oncol Biol Phys; 2022 Jul; 113(4):752-758. PubMed ID: 35450753 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations. Cortiula F; De Ruysscher D; Steens M; Wijsman R; van der Wekken A; Alberti M; Hendriks LEL Eur J Cancer; 2023 May; 184():172-178. PubMed ID: 36931075 [TBL] [Abstract][Full Text] [Related]
10. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer. Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272 [TBL] [Abstract][Full Text] [Related]
11. Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer. Edwards DM; Sankar K; Alseri A; Jiang R; Schipper M; Miller S; Dess K; Strohbehn GW; Elliott DA; Moghanaki D; Ramnath N; Green MD; Bryant AK Int J Radiat Oncol Biol Phys; 2024 Mar; 118(4):963-970. PubMed ID: 37793573 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349 [TBL] [Abstract][Full Text] [Related]
13. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. Desilets A; Blanc-Durand F; Lau S; Hakozaki T; Kitadai R; Malo J; Belkaid W; Richard C; Messaoudene M; Cvetkovic L; Kazandjian S; Tehfe M; Florescu M; Jao K; Daaboul N; Owen S; Shieh B; Agulnik J; Cohen V; Charbonneau C; Marcoux N; Blais N; Leighl NB; Bradbury PA; Liu G; Shepherd FA; Bahig H; Routy B; Sacher A; Elkrief A Eur J Cancer; 2021 Jan; 142():83-91. PubMed ID: 33242835 [TBL] [Abstract][Full Text] [Related]
14. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes. Rajappa S; Sharma S; Prasad K Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419 [TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy - single institute experience. Vrankar M; Stanic K; Jelercic S; Ciric E; Vodusek AL; But-Hadzic J Radiol Oncol; 2021 Nov; 55(4):482-490. PubMed ID: 34821136 [TBL] [Abstract][Full Text] [Related]
16. Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC). Liu J; Bratton E; Yu X; Ladbury C; Wagner J; West H; Massarelli E; Salgia R; Pathak R; Villaflor V; Villalona-Calero M; Amini A Am J Clin Oncol; 2022 Feb; 45(2):49-54. PubMed ID: 34991107 [TBL] [Abstract][Full Text] [Related]
17. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer. Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139 [TBL] [Abstract][Full Text] [Related]
18. Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone. Abe T; Saito S; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S Thorac Cancer; 2021 Jan; 12(2):245-250. PubMed ID: 33289347 [TBL] [Abstract][Full Text] [Related]
19. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer. Kashihara T; Nakayama Y; Okuma K; Takahashi A; Kaneda T; Katagiri M; Nakayama H; Kubo Y; Ito K; Nakamura S; Takahashi K; Inaba K; Murakami N; Saito T; Okamoto H; Itami J; Kusumoto M; Ohe Y; Igaki H Radiother Oncol; 2023 Mar; 180():109454. PubMed ID: 36640944 [TBL] [Abstract][Full Text] [Related]
20. Use of durvalumab in stage III non-small-cell lung cancer based on eligibility for the PACIFIC study. Boys E; Gao B; Hui R; da Silva I; Hau E; Gee H; Nagrial A Thorac Cancer; 2023 Feb; 14(6):563-572. PubMed ID: 36627112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]